Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Duke Clinical Research Institute, Durham, NC, USA.
Psychiatry Investig. 2009 Jun;6(2):55-8. doi: 10.4306/pi.2009.6.2.55. Epub 2009 Jun 30.
Pregabalin is a newly developed synthetic gamma-aminobutyric acid (GABA) that is approved for the treatment of fibromyalgia and several neuropathy. It has been proven to show analgesic, anxiolytic, anticonvulsant and sleep enhancement effects, which could be applicable in the treatment of a variety of psychiatric disorders. There have been consistent reports that unexplained somatic symptoms (i.e., pain) may be a part of psychiatric disorders such as major depressive disorder (MDD) and anxiety disorders. Previous researches have also suggested the possible therapeutic potential of anticonvulsants as augmentation therapy or monotherapy in the treatment of mood disorders and anxiety disorders. Hence this short perspective tries to prompt and facilitate a shifting of researchers' attention to potential neuropsychotropic drug role of pregabalin to treat a wide range of neuropsychiatric disorders.
普瑞巴林是一种新开发的合成 γ-氨基丁酸（GABA），已被批准用于治疗纤维肌痛和几种神经病变。已证明它具有镇痛、抗焦虑、抗惊厥和改善睡眠的作用，可适用于治疗多种精神疾病。一直有一致的报告表明，不明原因的躯体症状（即疼痛）可能是精神疾病的一部分，如重度抑郁症（MDD）和焦虑症。先前的研究还表明，抗惊厥药作为增效治疗或单药治疗，可能具有治疗心境障碍和焦虑症的潜在治疗潜力。因此，这篇短文旨在促使和促使研究人员将注意力转向普瑞巴林作为治疗广泛神经精神疾病的潜在神经精神药物的作用。
